Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N550H |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 N550H (corresponds to N549H in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550H results in increased Fgfr2 kinase activity, as well as increased Fgfr2 phosphorylation and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597). |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N550H |
Transcript | NM_022970.4 |
gDNA | chr10:g.121498522T>G |
cDNA | c.1648A>C |
Protein | p.N550H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144913 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 N550H | Advanced Solid Tumor | decreased response | Dovitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597). | 23908597 |
FGFR2 N550H | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597). | 23908597 |
FGFR2 N550H | Advanced Solid Tumor | resistant | PD173074 | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597). | 23908597 |
FGFR2 N550H | Advanced Solid Tumor | predicted - sensitive | KIN-3248 | Preclinical - Biochemical | Actionable | In a preclinical study, KIN-3248 inhibited kinase activity of FGFR2 N550H in an in vitro assay (PMID: 38437671). | 38437671 |
FGFR2 N550H | Advanced Solid Tumor | predicted - sensitive | TYRA-200 | Preclinical - Biochemical | Actionable | In a preclinical study, TYRA-200 inhibited FGFR2 N550H in an in vitro assay (Eur J Cancer 2022 Vol 174, Supp 1:S16). | detail... |